Titre : | International Journal of Drug Policy, Vol.72 - October 2019 - Striving towards the elimination of HCV infection among PWID |
Auteurs : | J. GREBELY, Éditeur scientifique ; C. TRELOAR, Éditeur scientifique ; J. BRUNEAU, Éditeur scientifique ; J. V. LAZARUS, Éditeur scientifique ; B. HAJARIZADEH, Éditeur scientifique |
Type de document : | Bulletin : Périodique |
Paru le : | 01/10/2019 |
Année de publication : | 2019 |
Format : | 1-198 |
Langues: | Anglais |
Discipline : | MAL (Maladies infectieuses / Infectious diseases) |
Mots-clés : |
Thésaurus mots-clés HEPATITE ; TRAITEMENT |
Note de contenu : |
CONTENTS:
- Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. Grebely J., Hajarizadeh B., Lazarus J.V., Bruneau J., Treloar C., International Network on Hepatitis in Substance Users, p. 1-10. - Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs. Hoj S.B., Jacka B., Minoyan N., Artenie A.A., Bruneau J., p. 11-23. - Characterising the policy influence of peer-based drug user organisations in the context of hepatitis C elimination. Brown G., Perry G.-E., Byrne J., Crawford S., Henderson C., Madden A., et al., p. 24-32. - Contact tracing for hepatitis C: The case for novel screening strategies as we strive for viral elimination. Katzman C., Mateu-Gelabert P., Kapadia S.N., Eckhardt B.J., p. 33-39. - Evidence-making hepatitis C cure: Towards a science that knows more carefully. Rhodes T., Lancaster K., p. 40-46. - Rural risk environments for hepatitis c among young adults in Appalachian Kentucky. Cloud D.H., Ibragimov U., Prood N., Young A.M., Cooper H.L.F., p. 47-54. - Mapping the hepatitis C cascade of care in people attending drug treatment services in England: A data linkage study. Ireland G., Simmons R., Hickman M., Eastwood B., Ramsay M., Mandal S., p. 55-60. - Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. Rojas Rojas T., Di Beo V., Delorme J., Barre T., Mathurin P., Protopopescu C., et al., p. 61-68. - Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs? Makarenko I., Artenie A., Hoj S., Minoyan N., Jacka B., Zang G., et al., p. 69-76. - Making sense of 'side effects': Counterpublic health in the era of direct-acting antivirals. Bryant J., Rance J., Hull P., Mao L., Treloar C., p. 77-83. - Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department. Hutton J., Doyle J., Zordan R., Weiland T., Cocco A., Howell J., et al., p. 84-90. - Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study. Williams B., Howell J., Doyle J., Thompson A.J., Draper B., Layton C., et al., p. 91-98. - An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study. Alavi M., Poustchi H., Merat S., Kaveh-ei S., Rahimi-Movaghar A., Shadloo B., et al., p. 99-105. - Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada. Selfridge M., Cunningham E.B., Milne R., Drost A., Barnett T., Lundgren K., et al., p. 106-113. - What is killing people with hepatitis C virus infection? Analysis of a population-based cohort in Canada. Krajden M., Cook D.A., Wong S., Yu A., Butt Z.A., Rossi C., et al., p. 114-122. - Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting. Overton K., Clegg J., Pekin F., Wood J., McGrath C., Lloyd A., et al., p. 123-128. - Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston. Beiser M.E., Smith K., Ingemi M., Mulligan E., Baggett T.P., p. 129-137. - Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs. Williams B.E., Nelons D., Seaman A., Witkowska M., Ronan W., Wheelock H., et al., p. 138-145. - Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review. Socias M.E., Karamouzian M., Parent S., Barletta J., Bird K., Ti L., p. 146-159. - Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. Barocas J.A., Morgan J.R., Fiellin D.A., Schackman B.R., Eftekhari Yazdi G., Stein M.D., et al., p. 160-168. - Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: A systematic review. Caven M., Malaguti A., Robinson E., Fletcher E., Dillon J.F., p. 169-176. - Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, Canada. Holeksa J., Magel T., Alimohammadi A., Thiam A., Yung R., Chu L., et al., p. 177-180. - High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. Valencia J., Alvaro-Meca A., Troya J., Cuevas G., Gutiérrez J., Morro A., et al., p. 181-188. - Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016. Marco A., Guerrero R.A., Vergara M., Gallego C., Solé C., Planella R., et al., p. 189-194. - Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia. Harney B.L., Whitton B., Lim C., Paige E., McDonald B., Nolan S., et al., p. 195-198. |
Cote : | Abonnement |
Lien : | https://www.sciencedirect.com/journal/international-journal-of-drug-policy/vol/72 |
Dépouillements
Ajouter le résultat dans votre panierArticle : Périodique
J. GREBELY ;
B. HAJARIZADEH ;
J. V. LAZARUS ;
J. BRUNEAU ;
C. TRELOAR ;
International Network on Hepatitis in Substance Users
|
There have been major strides towards the World Health Organization goal to eliminate hepatitis C virus (HCV) infection as a global public health threat. The availability of simple, well-tolerated direct-acting antiviral therapies for HCV infect[...]
Article : Périodique
T. ROJAS ROJAS ;
V. DI BEO ;
J. DELORME ;
T. BARRÉ ;
P. MATHURIN ;
C. PROTOPOPESCU ;
F. BAILLY ;
M. COSTE ;
N. AUTHIER ;
M. P. CARRIERI ;
B. ROLLAND ;
F. MARCELLIN
|
Background: In the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently documented in key populations such as people with opioid dependence. Access to opioid ag[...]
Article : Périodique
M. KRAJDEN ;
D. A. COOK ;
S. WONG ;
A. YU ;
Z. A. BUTT ;
C. ROSSI ;
M. DARVISHIAN ;
M. ALVAREZ ;
J. A. BUXTON ;
M. TYNDALL ;
N. Z. JANJUA
|
Background: Persons with hepatitis C virus (HCV) infection are at risk of mortality from both chronic liver disease and HCV acquisition risk activities. We compared causes of death among HCV positive and negative individuals to characterize cont[...]
Article : Périodique
M. E. SOCIAS ;
M. KARAMOUZIAN ;
S. PARENT ;
J. BARLETTA ;
K. BIRD ;
L. TI
|
Background: Despite the key role that people who inject drugs (PWID) play in the hepatitis C virus (HCV) epidemic, HCV treatment rates among this population have been historically low. Integrated models of HCV and substance use care have the pot[...]
Article : Périodique
M. CAVEN ;
A. MALAGUTI ;
E. ROBINSON ;
E. FLETCHER ;
J. F. DILLON
|
Background: A systematic review was conducted to determine the impact of Hepatitis C (HCV) treatment on substance use behaviour in people who inject drugs (PWID).
Methods: A search for peer reviewed journal articles from 1991 to present day was[...]
Article : Périodique
J. HOLEKSA ;
T. MAGEL ;
A. ALIMOHAMMADI ;
A. THIAM ;
R. YUNG ;
L. CHU ;
D. TRUONG ;
B. CONWAY
|
Introduction: Concerns about reinfection may be limiting HCV treatment uptake among people who use drugs (PWUD), with rates of 17.1/100 person-years in some cohorts. The aim of this study was to evaluate reinfection following successful treatmen[...]
Exemplaires
Disponibilité |
---|
aucun exemplaire |
Accueil